NeOnc Technologies Holdings(NTHI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NTHI NeOnc Technologies Holdings

交易中 08-21 15:42:46 EDT

4.66

+0.10

+2.30%

最高4.89	最低4.39	成交量11.70万
今开4.61	昨收4.56	日振幅10.96%
总市值1.21亿	流通市值4,120万	总股本2,601万
成交额53.00万	换手率1.32%	流通股本883.29万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NTHI","market":"US","secType":"STK","nameCN":"NeOnc Technologies Holdings","latestPrice":4.6647,"timestamp":1787341341521,"preClose":4.56,"halted":0,"volume":116979,"delay":0,"changeRate":0.02296052631578953,"floatShares":8832900,"shares":26013100,"eps":-1.82,"marketStatus":"交易中","change":0.1047,"latestTime":"08-21 15:42:46 EDT","open":4.61,"high":4.8899,"low":4.39,"amount":530024.596302,"amplitude":0.109627,"askPrice":4.74,"askSize":65,"bidPrice":4.62,"bidSize":203,"shortable":3,"etf":0,"ttmEps":-1.82,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787342400000},"marketStatusCode":2,"adr":0,"listingDate":1711512000000,"exchange":"NASDAQ","adjPreClose":4.56,"preHourTrading":{"tag":"盘前","latestPrice":4.74,"preClose":4.56,"latestTime":"09:02 EDT","volume":1497,"amount":7123.2598302,"timestamp":1787317341481,"change":0.18,"changeRate":0.039474,"amplitude":0.035088},"postHourTrading":{"tag":"盘后","latestPrice":4.56,"preClose":4.56,"latestTime":"19:59 EDT","volume":70,"amount":315.4,"timestamp":1787270347025,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.314642},"requestUrl":"/m/hq/s/NTHI/tweets","defaultTab":"tweets","newsList":[{"id":"1168273292","title":"NeOnc Technologies Holdings 公布鼻内给药 Neo100 针对复发性 IDH1 突变型高级别胶质瘤的积极 2a 期顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1168273292","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168273292?lang=zh_cn&edition=full","pubTime":"2026-08-12 20:01","pubTimestamp":1786536077,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings 宣布，其针对复发性 IDH1 突变型高级别胶质瘤患者开发的鼻内给药产品 Neo100，在 2a 期临床试验中取得了积极的顶线数据。这一结果无疑为攻克这一难治性脑瘤带来了新的希望，并进一步验证了该公司在肿瘤精准治疗领域的创新实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120133280","title":"Neonc科技公布2026年第二季度财报，并确认将于8月12日发布Neo100二期a阶段关键数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1120133280","media":"美股速递","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120133280?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:02","pubTimestamp":1786366978,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings（NTHI）今日正式披露了其2026年第二季度的财务表现。与此同时，该公司还郑重确认，其备受瞩目的Neo100二期a阶段临床试验的顶线数据，定于8月12日揭晓。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177518473","title":"Neonc Technologies：FDA认定其CMC开发方案合理，但附加生产变更条件","url":"https://stock-news.laohu8.com/highlight/detail?id=1177518473","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177518473?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:17","pubTimestamp":1784121457,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局在审阅Neonc Technologies Holdings的CMC开发方案后，认为其整体思路合理。然而，监管机构针对生产过程中的变更提出了附加条件，要求公司在实施相关调整时必须满足特定要求。CMC开发是药物获批上市的关键环节，涉及药品的生产工艺、质量控制和稳定性等核心方面。FDA的认可意味着公司在该领域的技术路径基本获得肯定，而附加条件则明确了后续优化生产中需遵循的监管框架。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122121747","title":"Neonc Technologies获阿联酋IND批准推进Neo100，全球开发版图扩张，静待二期数据里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1122121747","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122121747?lang=zh_cn&edition=full","pubTime":"2026-06-23 21:05","pubTimestamp":1782219921,"startTime":"0","endTime":"0","summary":"Neonc Technologies公司宣布，其候选药物Neo100已获得阿联酋（UAE）的新药临床试验（IND）批准。这一进展标志着该公司全球开发战略的进一步拓展，为即将到来的二期临床试验数据里程碑铺平了道路。随着监管绿灯的亮起，Neo100在中东地区的临床开发路径得以开启，有望加速其作为潜在疗法的全球评估进程。公司正积极筹备后续的临床工作，市场也正密切关注其后续关键数据的发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172142321","title":"Neonc Technologies拟通过私募发行最多500万美元A系列可转换优先股 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1172142321","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172142321?lang=zh_cn&edition=full","pubTime":"2026-06-12 18:05","pubTimestamp":1781258739,"startTime":"0","endTime":"0","summary":"根据提交至美国证券交易委员会（SEC）的文件，Neonc Technologies Holdings计划以私募方式发行最多价值500万美元的A系列可转换优先股。\n此次融资活动旨在为公司注入新的资本，以支持其业务发展计划。可转换优先股通常为投资者提供固定股息，并赋予其在特定条件下将股份转换为普通股的权利。\n该交易的具体条款，包括转换价格、股息率及最终发行规模，将在后续的正式协议中最终确定。公司通过此类非公开融资，可更为灵活地获取发展所需资金。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188238458","title":"Neonc Technologies Holdings, Inc. 董事长兼CEO斥资约30万美元购入公司股票，并就2025年财务业绩提供说明","url":"https://stock-news.laohu8.com/highlight/detail?id=1188238458","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188238458?lang=zh_cn&edition=full","pubTime":"2026-04-14 21:02","pubTimestamp":1776171739,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings, Inc. (以下简称\"公司\")今日宣布，其董事长兼首席执行官近期已斥资约30万美元，在公开市场购入了公司股票（股票代码：NTHI）。此次内部人士的增持行为，彰显了公司核心管理层对未来发展的坚定信心。\n与此同时，公司管理层也针对近期公布的2025年财务业绩提供了进一步的背景说明和解读，旨在帮助投资者更全面地理解公司的财务状况与战略方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155729765","title":"Neonc Technologies Holdings公司——Neo100二期a阶段试验完成患者招募，中期数据预计2026年8月公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1155729765","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155729765?lang=zh_cn&edition=full","pubTime":"2026-04-01 21:05","pubTimestamp":1775048712,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings公司宣布，其创新药物Neo100的二期a阶段临床试验已完成全部患者入组工作。该项研究的重要里程碑为后续数据评估奠定基础，中期研究结果预计将于2026年8月正式披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115650367","title":"Neonc Technologies公布口服Neo212一期剂量递增试验结果：确定二期推荐剂量 管理层将于美东时间上午9点召开KOL电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1115650367","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115650367?lang=zh_cn&edition=full","pubTime":"2026-03-04 21:03","pubTimestamp":1772629426,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings宣布口服抗癌药物Neo212的一期临床试验剂量递增阶段数据。研究明确了药物的安全剂量范围与毒性特征，并成功确定了二期临床试验推荐使用剂量。\n公司管理层将于美东时间今日上午9点举办关键意见领袖电话会议，深入解读临床数据及后续开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neonc.com","stockEarnings":[{"period":"1week","weight":0.4206},{"period":"1month","weight":0.3531},{"period":"3month","weight":-0.1461},{"period":"6month","weight":-0.5417},{"period":"1year","weight":-0.1453},{"period":"ytd","weight":-0.4486}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.0227},{"period":"6month","weight":0.1061},{"period":"1year","weight":0.1951},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neonc Technologies Holdings, Inc.于2023年1月5日注册成立，为特拉华州公司。作为一家临床阶段的生物制药公司，该公司一直专注于建立颅内恶性肿瘤的治疗方法，即位于大脑的侵袭性癌症。这些癌症类型包括原发性脑癌，如胶质母细胞瘤，和继发性脑癌，它们是通过全身其他癌症的转移扩散而来的，如黑色素瘤或乳腺癌和肺癌。大脑局限性恶性肿瘤特别难以治疗，因为血脑屏障阻止了大多数药物治疗剂有效进入大脑。因此，这些患者面临着预后不良和平均预期寿命缩短的问题。NeOnc正在开发新的药物递送方法，用于与新的候选药物联合使用。","exchange":"NASDAQ","name":"NeOnc Technologies Holdings","nameEN":"NeOnc Technologies Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NeOnc Technologies Holdings(NTHI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供NeOnc Technologies Holdings(NTHI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"NeOnc Technologies Holdings,NTHI,NeOnc Technologies Holdings股票,NeOnc Technologies Holdings股票老虎,NeOnc Technologies Holdings股票老虎国际,NeOnc Technologies Holdings行情,NeOnc Technologies Holdings股票行情,NeOnc Technologies Holdings股价,NeOnc Technologies Holdings股市,NeOnc Technologies Holdings股票价格,NeOnc Technologies Holdings股票交易,NeOnc Technologies Holdings股票购买,NeOnc Technologies Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NeOnc Technologies Holdings(NTHI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供NeOnc Technologies Holdings(NTHI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}